甲氧氯普胺治疗迟发性运动障碍。
Metoclopramide in tardive dyskinesia.
机构信息
Lecturer in Pharmacology, Govt. Medical College, Nagpur.
出版信息
Indian J Psychiatry. 1983 Apr;25(2):134-7.
The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been compared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia following long term neuroleptic therapy. Tardive dyskinesia rating scores were decreased significantly (P<0.01) 6 hours after administration of metoclopramide 20 mg and 40 mg when compared with placebo. Reduction of tardive dyskinesia by metoclopramide-a D(2)receptor blocking agent suggest that D(2)receptors may be involved in the mediation of this syndrome.
一项双盲随机研究比较了甲氧氯普胺（10mg、20mg 和 40mg 单剂量静脉注射）与安慰剂（生理盐水）在 10 例长期抗精神病药物治疗后出现迟发性运动障碍患者中的疗效。与安慰剂相比，甲氧氯普胺 20mg 和 40mg 给药 6 小时后迟发性运动障碍评分显著降低（P<0.01）。甲氧氯普胺（D2 受体阻滞剂）对迟发性运动障碍的抑制作用表明 D2 受体可能参与了该综合征的发生。
Zotero 插件